国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (8): 615-618.doi: 10.3760/cma.j.issn.1673-422X.2017.08.015

• 综述 • 上一篇    下一篇

微小RNA与卵巢癌

化定超, 王新宇   

  1. 310006 杭州,浙江大学医学院附属妇产科医院妇瘤科;浙江大学医学院附属第四医院妇产科
  • 出版日期:2017-08-08 发布日期:2017-07-21
  • 通讯作者: 王新宇,Email: wangxy@zju.edu.cn E-mail:wangxy@zju.edu.cn

MicroRNAs and ovarian cancer

Hua Dingchao, Wang Xinyu   

  1. Department of Gynecologic Oncology, Affiliated Women′ s Hospital,  Zhejiang University School of Medicine, Hangzhou 310006, China; Department of Obstetrics and Gynecology, Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China
  • Online:2017-08-08 Published:2017-07-21
  • Contact: Wang Xinyu, Email: wangxy@zju.edu.cn E-mail:wangxy@zju.edu.cn

摘要: 微小RNA(miRNA)的异常表达与卵巢癌的发生发展密切相关,其参与调控卵巢癌的发生、侵袭和转移以及抗癌药物耐药性形成等过程。作为一种重要的生物学标志物,miRNA有望成为卵巢癌早期诊断与预后判断的新靶点,为卵巢癌的治疗提供新的途径。

关键词: 微RNAs, 卵巢肿瘤, 抗药性, 肿瘤, 上皮-间质转化, 肿瘤浸润

Abstract: The abnormal expressions of microRNAs (miRNAs) are closely related to the genesis and development of ovarian cancer. MiRNAs are involved in carcinogenesis and progression, invasion and metastasis as well as drug resistance. As a kind of significant biomarker, miRNAs are expected to be novel targets for the early diagnosis and prognostic evaluation of ovarian cancer, which provide new ways for the therapy of ovarian cancer.

Key words: MicroRNAs, Ovarian neoplasms, Drug resistance, neoplasms, Epithelialmesenchymal transition, Neoplasm invasiveness